A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs IX 01 (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Sponsors Ixchelsis
- 20 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.
- 20 Feb 2017 Planned initiation date changed from 20 Feb 2017 to 22 Feb 2017.